PAA 10.3% 37.5¢ pharmaust limited

The Turning Point

  1. 11,411 Posts.
    lightbulb Created with Sketch. 5727
    As we can see considerable Buyers queing its that time when Value has to be realized.

    The reason the buyers are forming an orderly que is because they see Commercial Opportunity and want to enter ownership and participate in Pharmausts success..

    The Entry Price should be what You the Shareholder have asked for ,, it's that simple to create The Turning Point... The Phase II trial is tantalizingly close now, the Traders will be circling , I speak from experience, there is a Unique Commercial Opportunity with Pharmaust.

    I do not know of another Australian Baby Biotech that has an INKED agreement with a juggernaut of the likes of Elanco , The Elanco Option is hugely significant. It is only well respected individuals of the likes of Roger Aston who can gain an audience with companies of the caliber of Elanco plus to come away with an inked Option , in simple speak the Option is a Global Manufacturing and Distribution Deal . This is part of Elanco's core Business, Primary being Animal Health , our specific sector Close Companion Animals.

    I'm 90% a Trader , The reason being I dont have to wait for a venture to reach commercialisation to gain a return.. The reason I chose this method is there is a huge void,, a chasm between having a great product/treatment and commercialisation , Approved Product by Regulators, Compliant Packaging, Manufacturing, Warehousing , Distribution, Product Placement, Marketing and Administering Sales ... Pharmaust have one of the most competent Companies in the world who is ready and prepared to carry out those functions. Elanco are the read Deal , you can Google their acquisitions, they have a team that specialise in it... plus Elanco have recently formed a division of sales professionals to "sell in K9 Oncology Treatments" .as before this sounds like "Hand In Glove" agreement.. my take is they are preparing..

    The Results from the Phase II K9 Oncology are a Milestone needed to achieve to progress to Human Trials, The K9 data is crucial not only is it the finish line for K9 Treatments but the real Start Line for Human Trials.

    Armed with the Elanco/Eli Lilly data of 20 years of MPL already being part of the Human Food Chain (sorry not Vegetarians) MPL has already gained FDA Approval so I truly believe after a RE-DO of the Previous Human Trials , again palatability was the headline that overshadowed the astounding results again mimicked by the Olivia Newtown John Cancer Foundation showing positive effect on 26 from 30 Human Cancers.
    Pharmaust / Elanco could apply for Fast Track Application or Purchase a Voucher (someone else's spot in the line) you could see a Commercial Paid Phase III Trial... this is where the the FDA allow the Treatment to be sold and the data gathered from paying patients is attributed to data that eventually demonstrates the Treatments ability to possibly Hold Human Cancers in Stasis,, Stopping the growth of Human Cancers.

    I believe for the privilege of ownership in the Pharmaust commercial venture ,,Buyers should at least pay the sellers what they ask.... Lock in $$ what You want ,, The Buyers are coming an no one wants to be 10th in the que,,, I'm picking next week ,, Confirmation of Dog 1 being recruited and being administered Dose 1 of Pharmapantal.

    The world is full of an endless supply of money,,,, there are only 300m PAA shares ,,rare in the scheme of things,,, Best of luck. Friday Fishing calls.


 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
37.5¢
Change
0.035(10.3%)
Mkt cap ! $146.4M
Open High Low Value Volume
34.5¢ 38.0¢ 34.5¢ $542.7K 1.474M

Buyers (Bids)

No. Vol. Price($)
1 14511 37.0¢
 

Sellers (Offers)

Price($) Vol. No.
37.5¢ 18443 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
37.0¢
  Change
0.035 ( 8.82 %)
Open High Low Volume
34.5¢ 38.0¢ 34.5¢ 757697
Last updated 15.59pm 28/03/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.